Zygomycosis
MONDO:0019136Any infection due to a fungus of the Zygomycota phylum. The disease typically involves the rhino-facial-cranial area, lungs, gastrointestinal tract, skin, or less commonly other organ systems. The infecting fungi have a predilection for invading vessels of the arterial system, causing embolization and subsequent necrosis of surrounding tissue.
Also known as: Mucormycosis, Zygomycota infectious disease, mucormycosis
43 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
New antifungal drug shows promise against deadly fungal infections
Disease control CompletedThis study tested the safety and effectiveness of the antifungal drug isavuconazole as a first treatment for Chinese patients with serious invasive fungal infections caused by Aspergillus or other molds. All 70 participants received the drug for up to 84 days (or 180 days for cer…
Phase: PHASE4 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
Pill vs. IV: could a new drug beat the standard for deadly lung fungus?
Disease control CompletedThis study tested whether the antifungal drug posaconazole (taken as a pill) works as well as the standard IV drug amphotericin B for treating a serious lung infection called pulmonary mucormycosis. The trial involved 82 adults with this rare but deadly infection. Researchers com…
Phase: PHASE2 • Sponsor: Post Graduate Institute of Medical Education and Research, Chandigarh • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Cresemba under the microscope: Real-World safety check for fungal infections
Disease control CompletedThis study looked at how safe and effective the drug Cresemba (isavuconazole) is for Korean patients with serious fungal infections like invasive aspergillosis or mucormycosis. Researchers tracked side effects and how well the drug worked in 94 adults. The goal was to confirm the…
Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
High-Dose antifungal drug tested against deadly zygomycosis
Disease control CompletedThis Phase 2 trial tested a high dose (10 mg/kg/day) of the antifungal drug liposomal amphotericin B (Ambisome) in 40 people with zygomycosis, a rare but serious fungal infection. The goal was to see if the high dose could effectively control the infection after 4 weeks of treatm…
Phase: PHASE2 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
Rural patients get Hospital-Level care at home in landmark trial
Disease control CompletedThis study looked at whether giving hospital-level care to acutely ill adults in their own homes in rural areas works well. 160 people with various conditions like infections, heart failure, or COPD took part. The goal was to see if this approach could lower costs and help patien…
Phase: NA • Sponsor: Brigham and Women's Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
New rapid test for infection and inflammation put to the test
Diagnosis CompletedThis study looked at how well a new, quick finger-prick test (LumiraDx CRP) measures CRP levels compared to a standard lab test. CRP is a marker of infection, inflammation, or tissue injury. 79 adults with symptoms of these conditions took part. The goal was to see if the new tes…
Sponsor: LumiraDx UK Limited • Aim: Diagnosis
Last updated Jun 27, 2026 13:07 UTC
-
New PET scan technique aims to sniff out hidden infections
Diagnosis CompletedThis early study tested whether a special PET scan using a radioactive form of vitamin B9 (11C-PABA) can help doctors see infections deep inside the body. Researchers scanned 13 healthy people and patients with known or suspected infections. The goal was to see if this method can…
Sponsor: Johns Hopkins University • Aim: Diagnosis
Last updated Jun 27, 2026 08:03 UTC
-
COVID-19's hidden toll: fungal infections rise in transplant patients
Knowledge-focused CompletedThis study looked back at 60 adult blood cancer patients who had stem cell transplants and later developed a rare fungal infection called mucormycosis. Researchers compared cases before COVID-19 (2015-2020) to during the pandemic (2020-2024) to see if the virus, new tests, or new…
Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:11 UTC
-
Real-World study examines Isavuconazole's effectiveness against deadly fungal infections
Knowledge-focused CompletedThis completed study looked at medical records of 307 adults in five European countries who were treated with the antifungal drug isavuconazole for serious fungal infections (invasive aspergillosis or mucormycosis). Researchers tracked how well the drug worked (clinical, radiolog…
Sponsor: Pfizer • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:03 UTC
-
ICU antibiotic dosing: what really matters?
Knowledge-focused CompletedThis study looked at 156 critically ill patients to find out what factors help achieve the right levels of beta-lactam antibiotics in the blood. Researchers collected clinical data and used therapeutic drug monitoring to see which patients reached target concentrations. The goal …
Sponsor: Centre Hospitalier Universitaire de Nīmes • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:01 UTC